Teva Pharmaceutical Q1 EPS Beats, Revenues Barely Miss

Teva Pharmaceutical Industries shares were up nearly 2% in Thursday’s pre-market after the drugmaker reported mixed Q1 results, with adjusted earnings beating expectations on higher revenues that narrowly missed views compiled by Capital IQ.

Q1 adjusted EPS was $1.06 per share, down from $1.20 per share a year earlier but three cents above the consensus.
Revenues rose to $5.63 billion from $4.81 billion but fell short of the $5.69 billion mean estimate. Teva’s board also approved an unchanged quarterly cash dividend of $0.34 per share, payable on June 22 to holders of record on June 5.

By Sonia Taylor